News

Dementia Affects Prognosis of ALS Patients, New Study Suggests

Analysis of a large group of patients with amyotrophic lateral sclerosis (ALS) has shown that patients who also have dementia at diagnosis are more likely to have bulbar-onset ALS, a subtype of the disease in which patients first experience symptoms in the head and neck, including trouble speaking or swallowing. These patients also…

Measuring Neurofilament Levels Might Improve Diagnosis of Early Symptomatic ALS

Routinely measuring neurofilaments in the blood and spinal fluid of people with amyotrophic lateral sclerosis (ALS) can help identify patients with early symptoms, concludes a recent study. Researchers led by Dr. Emily Feneberg of England’s University of Oxford presented the study, “Multicenter evaluation of neurofilaments in early symptom onset amyotrophic…

Verge Genomics Joins 4 Top Universities to Advance ALS Research

The company Verge Genomics, which uses genomic data for neuroscience therapeutics, announced that it will join specialized departments at four top universities to boost research in amyotrophic lateral sclerosis (ALS). The innovative industry-academic collaboration will combine machine learning with genomic, genetic, biological, and phenotypical data to accelerate the translation…

Disarm Therapeutics Receives Key Funding for ALS Therapy Development

Research into the development of new therapies to treat several traumatic, inflammatory, and neurodegenerative diseases including amyotrophic lateral sclerosis (ALS) received an important financial boost with the announcement by Disarm Therapeutics that it will receive $30 million in financing to develop treatments for axonal degeneration. Disarm was founded in 2016 as a…